Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity
- Joan Wither1Email author,
- Yong-chun Cai2,
- Sooyeol Lim3,
- Tamara McKenzie2,
- Nicole Roslin3,
- Jaime O Claudio2,
- Glinda S Cooper4,
- Thomas J Hudson5,
- Andrew D Paterson3,
- Celia MT Greenwood3,
- Dafna Gladman6,
- Janet Pope7,
- Christian A Pineau8,
- C Douglas Smith9,
- John G Hanly10,
- Christine Peschken11,
- Gilles Boire12,
- CaNIOS Investigators13 and
- Paul R Fortin6, 14
© Wither et al.; licensee BioMed Central Ltd. 2008
Received: 10 April 2008
Accepted: 10 September 2008
Published: 10 September 2008
Systemic lupus erythematosus is a genetically complex disease. Currently, the precise allelic polymorphisms associated with this condition remain largely unidentified. In part this reflects the fact that multiple genes, each having a relatively minor effect, act in concert to produce disease. Given this complexity, analysis of subclinical phenotypes may aid in the identification of susceptibility alleles. Here, we used flow cytometry to investigate whether some of the immune abnormalities that are seen in the peripheral blood lymphocyte population of lupus patients are seen in their first-degree relatives.
Peripheral blood mononuclear cells were isolated from the subjects, stained with fluorochrome-conjugated monoclonal antibodies to identify various cellular subsets, and analyzed by flow cytometry.
We found reduced proportions of natural killer (NK)T cells among 367 first-degree relatives of lupus patients as compared with 102 control individuals. There were also slightly increased proportions of memory B and T cells, suggesting increased chronic low-grade activation of the immune system in first-degree relatives. However, only the deficiency of NKT cells was associated with a positive anti-nuclear antibody test and clinical autoimmune disease in family members. There was a significant association between mean parental, sibling, and proband values for the proportion of NKT cells, suggesting that this is a heritable trait.
The findings suggest that analysis of cellular phenotypes may enhance the ability to detect subclinical lupus and that genetically determined altered immunoregulation by NKT cells predisposes first-degree relatives of lupus patients to the development of autoimmunity.
Systemic lupus erythematosus (SLE) has a complex genetic basis, with genome-wide scans demonstrating significant or suggestive linkage between SLE and multiple chromosomal regions [1–3]. Despite the recent success of genome-wide association studies, the precise informative allelic polymorphisms contained within many of these regions remain unidentified [4, 5]. This lack of knowledge reflects the facts that most linkage and association studies have investigated the association with the global phenotype of lupus, which is clinically heterogeneous, and that multiple genes act in concert to produce lupus, each having a relatively minor effect. Given this complexity, analysis of subclinical phenotypes may increase the power to detect basic pathogenic mechanisms and to define genetic susceptibility more precisely.
Murine models of lupus exhibit genetic complexity similar to that in their human counterparts . However, in murine lupus study of allelic polymorphisms has been greatly aided by the ability to create congenic mice in which a single susceptibility allele, or small cluster of alleles, are back-crossed onto a normal genetic background. Notably, these congenic mice frequently exhibit subclinical phenotypes that are characterized by production of anti-nuclear antibodies (ANAs) and/or cellular changes indicative of increased B-cell or T-cell activation [7–9]. These findings suggest that the relatives of lupus patients, while lacking the full complement of genes required for development of clinical SLE, may share sufficient lupus susceptibility alleles to develop subclinical immunologic phenotypes. This concept is supported by the well documented observation that first-degree relatives of lupus patients have an increased prevalence of ANAs and other lupus-associated autoantibodies as compared with the general population [10, 11], and these phenotypes have successfully been used to map genetic loci that promote production of autoantibodies in lupus patients and their family members [12, 13].
Despite a relative abundance of data examining serologic phenotypes in the family members of lupus patients, relatively little is known about the cellular phenotype of these individuals. Lupus patients have a number of cellular phenotypic abnormalities, including the following: increased numbers of autoantibody secreting B cells [14, 15]; increased numbers of recently activated T and B cells [16–21]; altered proportions of naïve and memory T and B cell populations [17, 21–23]; and deficiencies of regulatory T-cell subsets such as natural killer (NK)T [24, 25] and T-regulatory (Treg) cells [26–28]. Here we examined whether first-degree relatives of lupus patients share some of these distinctive cellular abnormalities.
Materials and methods
Subjects and data collection
All patients fulfilled four or more of the revised 1997 American College of Rheumatology criteria for the classification of SLE and had two living parents who agreed to participate in the study. In total 144 patients, 288 parents, and 79 siblings were investigated. Population control individuals for the lupus patients were obtained by random digit dialing, which permitted general matching for geographic area. Additional control individuals matching the age distribution of the parents of the lupus patients were obtained through advertisements at the University Health Network and local community centers. Control individuals with a family history of lupus were excluded from the study. The study was approved by the Research Ethics Board of the University Health Network and each participating recruitment center.
After providing an informed consent, all subjects had blood drawn for isolation of DNA, cellular analysis and serologic testing, and completed a case report questionnaire. This form included basic information on demographics, family history, lifestyle and medical history, including specific questions on autoimmune diseases, medications, and comorbidities. In addition, the physicians of patients and family members with lupus completed a questionnaire, which enabled calculation of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a validated measure of lupus disease activity and damage.
Heparinized whole peripheral blood was transported by courier overnight at room temperature, and the following day, approximately 16 to 20 hours after blood drawing, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation. All samples were handled similarly regardless of the city of origin, and there was no difference in the time-to-analysis of samples from patients, family members, or control individuals. Isolated PBMCs were stained with various combinations of conjugated mAbs, to discriminate between cellular populations and to identify activated cells. Stained cells were fixed with 2% paraformaldehyde and analyzed by flow cytometry using a FACScalibur instrument (BD Biosciences, Missisauga, ON, Canada). The following conjugated mAbs were obtained from BD Biosciences: allophycocyanin-conjugated anti-CD3 (UHT1), anti-CD20 (2H7), anti-CD4 (RPA-T4), and anti-CD8 (RPA-T8); PE-conjugated IgG2b (27–35), IgG1 (MOPC-21), and anti-CD8 (RPA-T8), anti-CD45RO (UCHL1), anti-CD38 (H1T2), anti-CD69 (FN50), and anti-CD27 (M-T271); and FITC-conjugated IgG1 (MOPC-21), IgG2a (G155-178), and anti-CD4 (RPA-T4), anti-CD45RA (HI100), anti-CD27 (MT271), anti-CD80 (L307.4), anti-CD86 (2331 [FUN-1]), and anti-CD25 (M-A251). mAbs specific for Vα24 (C15) and Vβ11 (C21) were obtained from Immunotec (Marseille, France).
For most cellular populations 20,000 events were analyzed; however, 50,000 events were examined for enumeration of activated B cells and 200,000 lymphoid events for quantitation of NKT and Treg cells. The number of lymphocytes per milliliter was calculated from the number of PBMCs obtained per milliliter blood and the proportion of lymphocytes in the total cellular population, as determined by flow cytometry, acquiring all events.
In preliminary experiments it was determined that the delay in isolation of the PBMCs had no impact on cell number and viability (>95%), activation status, or the relative proportions of the majority of cellular populations within the lymphocyte gate in lupus patients and control individuals. However, the proportion of plasma cells within the PBMC population was significantly reduced after overnight transport. Because the majority of these cells are not contained within the lymphoid gate, the loss of this cell population had minimal impact on the proportions of the other cell populations examined.
Serum samples were screened for ANA at a 1:40 dilution using a kit with HEp-2 cell coated slides, as per the manufacturer's instructions (Antinuclear Antibody Test Kit with Stabilized Substrate, Antibodies Incorporated). Immunofluorescence was quantified using Image J1.37C software on digital images obtained with a Zeiss Axioplan 2 imaging microscope. Samples were graded based upon the percent of positive control staining above negative control staining, with a positive test being >25% above background. Anti-double-stranded DNA (dsDNA) antibody levels were determined by an in house ELISA, using calf thymus dsDNA as a substrate.
All data were verified and double entered in an Access database. Differences for various cellular phenotypes between groups were estimated using the Wilcoxon test and using the van Elteren test, which is a rank-based Wilcoxon nonparametric test that uses weighted stratification to control for the effect of covariates . Some cellular phenotypes exhibited strong deviations from normal distributions, even after log transformation; hence, the use of a nonparametric test minimizes the impact that outliers have on test statistics. Correlations between cellular phenotypes and disease activity, prednisone dose, and the levels of anti-dsDNA antibodies in the probands were determined using Spearman's rank correlation coefficient. The effect of age (stratified into <40 years, 40 to 60 years, and >60 years) and sex on the cellular variables in control individuals were determined using the Kruskal-Wallis test to assess independently the impacts of sex and age, and the Friedman rank sum test to assess the impact of age after controlling for sex and vice versa. Correlation of the NKT cell trait between relatives was determined using Spearman's rank correlation.
Demographic characteristics of 144 lupus patients
Value (mean ± SD)
5.35 ± 1.29
4 to 9
Disease duration (years)
9.26 ± 6.72
0.1 to 30.3
Age at diagnosis (years)
25.44 ± 9.18
6.0 to 51.3
5.61 ± 5.63
0 to 30
5.54 ± 3.91
0 to 18
0.94 ± 1.20
0 to 6
Prednisone dose (mg/day)
6.50 ± 9.83
0 to 60
Presence of multiple cellular abnormalities in lupus patients
Cellular phenotypes of lupus probands, first-degree relatives and controls
Cell population gated
Probands (n = 144)
First-degree relatives (n = 357)
Controls (n = 102)
Lymphocytes (× 106/ml)
0.63 ± 0.31*** (<0.0001)
0.83 ± 0.32
0.83 ± 0.37
14.54 ± 9.12
15.19 ± 7.10 (0.014)
13.84 ± 4.95
Naïve mature B cells
60.59 ± 16.54*
60.24 ± 15.06** (0.0051)
65.47 ± 11.65
Transitional B cells
14.63 ± 11.61* (0.009)
10.58 ± 8.04
10.11 ± 5.92
Activated naïve B cells
2.75 ± 4.72
1.50 ± 2.37
2.21 ± 5.51
Activated naïve B cells
6.93 ± 9.43
4.04 ± 5.64*** (0.0009)
6.44 ± 7.19
Memory B cells
23.40 ± 15.79
28.15 ± 15.67*
24.32 ± 11.50
Pre-germinal center B cells
2.77 ± 2.98*** (0.003)
1.49 ± 1.91
1.68 ± 3.06
Activated memory/pre-germinal center B cells
18.91 ± 11.69*
16.59 ± 9.53
15.84 ± 8.36
Activated memory/pre-germinal center B cells
12.12 ± 9.64*** (0.0039)
8.10 ± 6.52
9.00 ± 8.47
Recently activated B cells
20.40 ± 15.84*** (<0.0001)
13.05 ± 12.00
10.85 ± 8.93
63.44 ± 14.68
61.23 ± 12.68*
64.8 ± 9.70
CD4+ T cells
34.50 ± 12.77*** (0.0001)
40.06 ± 11.91
40.77 ± 9.98
CD8+ T cells
25.24 ± 11.01*
19.38 ± 9.30*
21.18 ± 7.46
0.06 ± 0.13*** (<0.0001)
0.08 ± 0.20*** (0.013)
0.11 ± 0.17
6.62 ± 4.30
6.39 ± 3.41
6.46 ± 2.98
Naive CD4+ cells
31.62 ± 14.41
25.06 ± 13.13**
29.05 ± 12.69
Memory CD4+ cells
37.10 ± 14.04*
41.63 ± 15.16 (0.0433)
40.27 ± 11.95
Recently activated CD4+ cells
10.55 ± 11.32*** (0.0001)
7.08 ± 8.56
5.95 ± 5.92
Naive CD8+ cells
62.36 ± 16.37*
53.92 ± 15.15**
58.61 ± 13.53
Memory CD8+ cells
15.75 ± 9.91*** (0.0027)
21.35 ± 11.09
20.29 ± 10.37
With the exception of the number of lymphocytes per milliliter (P = 0.0026), there was no significant correlation between the SLEDAI-2K and any of the cellular abnormalities examined. However, there was a significant correlation between prednisone dose or use of cytotoxic medications and several of the cellular phenotypes examined. An increased dose of prednisone was negatively correlated with the number of lymphocytes per milliliter (P < 0.0001) and the proportion of total B cells (P = 0.0007), transitional B cells (P = 0.0033) and CD4+ T cells (P = 0.0003), and positively correlated with the proportion of CD8+ T cells (P = 0.016), memory B cells (P = 0.034) and CD80+ (P = 0.033) or CD86+ (P = 0.0003) naïve B cells. In association with use of any cytotoxic drug, similar trends were observed for the proportion of total B cells (P < 0.0001), transitional B cells (P = 0.041), memory B cells (P = 0.0002), CD8+ T cells (P = 0.0038), and CD80+ (P = 0.0003) or CD86+ (P = 0.010) naïve B cells. In addition, use of cytotoxic drugs was associated with a reduced proportion of mature naïve B cells (P = 0.0020) and increased proportion of pre-germinal center cells (P = 0.021). In general, anti-malarial drug use was not associated with differences in proportions of the cellular populations. Notably, the majority of the cellular phenotypes that exhibited strong statistical differences between control individuals and probands did not vary with drug therapy or varied in a way that could not account for the differences observed.
Because our populations contained individuals of both sexes and with a broad age range, we questioned whether any of the cellular phenotypes varied with age or sex within our control population. Using a multivariate analysis incorporating age and sex, there was a significant correlation between increased age and an increased proportion of memory (CD45RA-RO+; P = 0.042) CD4+ cells and decreased proportions of CD3+ T cells (P = 0.002), CD8+ T cells (P = 0.003), and naïve CD4+ cells (CD45RA+RO-; P = 0.0007). Males had significantly reduced proportions of activated B cells (CD27-CD86+, P = 0.004; CD27+CD80+, P = 0.019; and CD27+CD86+, P = 0.0002) together with increased proportions of CD8+ T cells (P = 0.041). We therefore extended our statistical evaluation to control for these two covariates in all subsequent analyses where comparisons were being made between family groups and control individuals. As shown in Table 2, for all of the phenotypic differences that were significant at the P < 0.005 level between lupus patients and control individuals using the Wilcoxon test; strong statistical significance (P < 0.005) was retained when the van Elteren test (see Materials and methods, above) was used to take these covariates into account.
Cellular abnormalities in the family members of lupus patients
Although the majority of T-cell subsets examined were not different between the family members of lupus patients and control individuals, a decrease in the proportion of NKT cells was seen in the first-degree relatives of lupus patients compared with control individuals. Although the reduced proportion of NKT cells was not as pronounced as that seen in the probands (P = 0.0009 for relatives as compared with probands), it achieved statistical significance for both parent and sibling subpopulations when compared with control individuals (Figure 2). An increased proportion of CD4+ memory T cells was also seen in the first-degree relatives as a whole, but this difference was not consistent when the parents and siblings were analyzed separately. Notably, there was no correlation between the proportion of NKT cells and the proportions of CD86+ naïve B cells, mature naïve B cells, or memory CD4+ T cells in the lupus family members.
The reduced proportion of NKT cells in the family members of lupus patients correlates with the presence of a positive ANA
To determine whether the presence of positive ANA status was correlated with any of the cellular phenotypes identified in the relatives of our lupus patients, we measured IgG ANAs, using HEp-2 cells as a substrate. The frequency of ANA positive status at the time of study in our lupus patients was 85.2%, as compared with a rate of 4% ANA positivity in the control individuals (P < 0.001, Fisher's exact test). Consistent with previous reports, the first-degree relatives of lupus patients had a marked increase in the frequency of ANA positivity as compared with control individuals. Overall, 21.7% of family members were ANA+ (P < 0.001 versus control individuals), with a frequency of 23.9% in the mothers (P < 0.001), 22.4% in the fathers (P < 0.001), and 16% in the siblings (P = 0.008). Comparison of cellular phenotypes between ANA+ and ANA- relatives using the van Elteren test, with age and sex as covariates, revealed that only the proportion of NKT cells was correlated with a positive ANA status (P = 0.009); in family members the median proportion of NKT cells was significantly lower in individuals with a positive ANA (mean ± standard deviation = 0.032 ± 0.042, median = 0.014) as compared with those who were ANA negative (mean ± standard deviation = 0.086 ± 0.23, median = 0.029).
Because very few of the first-degree relatives had elevated levels of anti-dsDNA antibodies, the association between the presence of these autoantibodies and the proportion of NKT cells was not examined. However, there was no correlation between anti-dsDNA antibody levels and the proportion of NKT cells in the probands.
Association between autoimmune disease in the family members of lupus patients and a reduced proportion of NKT cells
Prevalence of self-reported autoimmune disease in the family members of lupus patients
Father (n = 144; n [%])
Mother (n = 144; n [%])
Sibling (n = 79; n [%])
Controls (n = 102; n [%])
Autoimmune disease: any
Every effort was made to confirm the presence of self-reported autoimmune disease, but only about 25% of autoimmune disease diagnoses could be confirmed at the time of analysis because of limitations on access to medical records. Of the 109 lupus relatives with at least one self-reported autoimmune disease, additional clinical information was available for 47, and 25 of these were confirmed positive. Because of the variability in confirmation of reported autoimmunity, cellular phenotypes were examined for both self-reported and confirmed autoimmune disease. For self-reported autoimmune disease, the presence of any autoimmune disease was associated with a significantly reduced number of lymphocytes per milliliter, reduced proportion of NKT cells, and increased proportion of CD69+ B cells in comparison with control individuals (P = 0.022, 0.0001 and 0.041, respectively, Wilcoxon test). When these data were adjusted for age and sex, using the van Elteren test, the differences in the number of lymphocytes per milliliter and proportion of NKT cells remained significant (P = 0.039 and 0.0006, respectively).
To examine the association with confirmed autoimmune disease, first-degree relatives with self-reported autoimmune disease for whom additional clinical information could not be obtained were removed from the analysis, and those who did not report an autoimmune disease or whose self-reported autoimmune disease was confirmed to be absent by medical records were considered to lack autoimmune disease. Only the reduced proportion of NKT cells was significantly associated with confirmed autoimmune disease (P = 0.006, using the Wilcoxon test), and this remained significant after adjustment for age and sex (P = 0.011, using the van Elteren test).
The reduced proportion of NKT cells in the first-degree relatives of lupus patients is independently associated with a positive ANA and autoimmune disease
Proportion of NKT cells in first-degree relatives of lupus patients, stratified by the presence of autoimmune disease and ANAs
Self-reported autoimmune disease
Confirmed autoimmune disease
0.089 ± 0.237 (0.030)
0.079 ± 0.198 (0.017)
0.092 ± 0.234 (0.035)
0.039 ± 0.054 (0.016)
0.040 ± 0.048 (0.022)
0.020 ± 0.029 (0.009)
0.036 ± 0.046 (0.019)
0.016 ± 0.029 (0.008)
The proportion of NKT cells is a heritable trait
To determine whether the proportion of NKT cells is genetically determined, we examined the correlation between the proportions of NKT cells between individuals within the same family. There was a significant correlation between the mid-parental value for the proportion of NKT cells and their proband's value (r = 0.223, P = 0.0079) as well as between the mid-parental value and their unaffected offspring's value (r = 0.416, P = 0.00093). A similar association was found between probands and their siblings (r = 0.280, P = 0.030).
In this study, most of the distinctive cellular abnormalities in lupus patients were not observed in their family members. Nevertheless, the first-degree relatives of lupus patients had reduced proportions of NKT cells and a relative shift toward increased proportions of memory and reduced proportions of naïve B and CD4+ T cells, as compared with population control individuals.
Although our study is not the first to examine cellular phenotypes in first-degree relatives of lupus patients, it is the first to perform such a comprehensive examination of the multiple different cellular phenotypic abnormalities in SLE. Previous studies seeking cellular abnormalities in the family members of lupus patients focused on a limited number of phenotypes, including examination of antibody-secreting cells, NK cells, and CD56+ T cells, and had significantly smaller sample sizes. Clark and coworkers  examined antibody-secreting cells in 25 first-degree relatives of lupus patients and found similar levels to those in control individuals. Similarly, there were no significant differences in the proportion or killing activity of NK cells between first-degree relatives of lupus patients and control individuals . The proportion of CD56+ T cells was also comparable in 45 first-degree relatives and control individuals . Although the authors argued that this indicates that NKT cells are not reduced in the relatives of lupus patients, studies indicate that CD56 is a poor marker for the immunoregulatory invariant NKT cell population because it is also expressed on some other peripheral blood T cells , whereas the Vα24+Vβ11+CD3+ cells examined in the present study correlate strongly with this population [30–32]. Indeed, a recent study  found no significant difference between the proportion of cells detected by anti-Vα24 and anti-Vβ11 staining, and those observed after staining with CD1d tetramers loaded with the α-galactosylceramide analog PBS57 or 6B11 (a mAb that recognizes the conserved region of the canonical Vα24Jα18 T cell receptor in invariant NKT cells).
Although a large number of cellular variables were assessed in this study, several findings suggest that the statistically significant differences observed between the first-degree relatives and control individuals did not occur by chance alone. In a study of 49 additional trios recruited after this study, the proportion of NKT cells in the first-degree relatives was similarly and significantly reduced as compared with control individuals (% NKT = 0.074 ± 0.12; P = 0.016 versus control individuals). Furthermore, the observation that the reduced proportion of NKT cells in first-degree relatives is independently and additively associated with positive ANA status and autoimmune disease strongly suggests that this reduction is of immunopathogenic and not just statistical relevance. Despite less striking differences in the proportions of memory and/or naïve B and CD4+ T cells, these changes may also be of pathogenic importance. We recently showed that a nonsynonymous single nucleotide polymorphism in the SLAM molecule Ly9 is linked to development of lupus in our collection of trios . We further demonstrated that this polymorphism, which is predicted to alter downstream signaling events, is associated with skewing of T-cell populations away from a naïve and toward a memory phenotype in the parents of our lupus patients.
NKT cells are a unique T-cell lineage that recognize glycolipid antigens within the context of CD1d, a nonclassical major histocompatibility complex (MHC) class I molecule. Upon activation, these cells are potent producers of immunoregulatory cytokines [31, 32]. Reduced proportions of these cells have been described in a number of human autoimmune conditions, including SLE [24, 25, 40], scleroderma [24, 40, 41], Sjögren's syndrome [24, 40], rheumatoid arthritis [24, 40, 42], multiple sclerosis [24, 40, 43], and type 1 DM [33, 44]. In several animal models of autoimmune disease, including the nonobese diabetic model of type 1 DM [45–48], experimental autoimmune encephalomyelitis[49, 50], and collagen-induced arthritis , deficiencies in NKT cells exacerbate disease whereas expansion and/or activation of NKT cells ameliorate disease. Results in murine models of lupus have been more conflicting, with both reduced and increased proportions of NKT cells proposed to exacerbate disease [52–56]. These disparities appear to arise, at least in part, from variations in the cytokines that are secreted by the NKT cells in the different lupus mouse models, with interleukin-4-secreting NKT cells inhibiting lupus and interferon-γ-secreting NKT cells exacerbating lupus [53, 54, 56, 57]. Similar findings have been observed in other autoimmune mouse models [45, 46, 49, 51, 58–60], suggesting that the immune mechanisms through which NKT cells act to suppress lupus and other autoimmune diseases are similar. This concept is further strengthened by our demonstration in this study that there is an association between reduced proportions of NKT cells and diverse autoimmune diseases in first-degree relatives of lupus patients.
Although deficiencies in NKT cells have been shown to be genetically linked or to precede the development of autoimmunity in murine models of autoimmune disease, data addressing these issues in humans are sparse. In type 1 DM, reduced proportions of NKT cells were observed in high-risk relatives with anti-pancreatic autoantibodies, suggesting that NKT cell deficiencies in this disease predate the development of clinical diabetes . Only a single study  has investigated the association between the proportion of NKT cells and disease activity. In this study, a subset of NKT cells, the CD4-CD8-Vα24JαQ expressing population, was examined, and the proportion of these cells was decreased only in active disease. In our study, we found no correlation between the proportion of total NKT cells and disease activity or drug therapy in our lupus patients, which suggests that the reduction in NKT cells in these patients does not arise as a secondary phenomenon in response to active disease or its treatment. Although first-degree relatives with positive ANA status and autoimmune disease had the lowest levels of NKT cells, significantly reduced proportions of NKT cells were still observed in family members without any clinical evidence of autoimmune disease or positive ANA status. This observation, together with the observation that the levels of NKT cells are significantly correlated between genetically related individuals within the same family, suggests that the reduced proportion of NKT cells is a heritable trait. These findings raise the possibility that one of the explanations for the clustering of multiple autoimmune disorders within the families of lupus patients is the presence of genetic polymorphisms that dictate NKT cell numbers and function, and that these changes precede the development of disease.
Aside from the changes in NKT cell numbers and the proportions of memory and/or naïve B and CD4+ T cells, first-degree relatives did not generally share the same immune abnormalities as the lupus probands. In particular, the marked B-cell activation phenotype that is characteristic of lupus was absent. We previously showed that the increased B-cell activation demonstrates only a weak correlation with disease activity and is present both in newly diagnosed, untreated lupus and clinically inactivate lupus (SLEDAI-2K = 0) . The findings in this report confirm these observations and demonstrate that development of positive ANA status in the relatives of lupus patients need not be associated with any markers of increased B-cell activation, suggesting that this marked B-cell activation phenotype develops after the immunologic events that lead to overt lupus. Although the levels of costimulatory molecules on B cells in the relatives of lupus patients were somewhat reduced in this study as compared with control individuals, and this achieved strong statistical significance in the case of CD86 expression in the CD27- naïve B-cell population, we were unable to replicate these findings in a subsequent study of 49 trios. This observation suggests that these differences are not biologically relevant and may have resulted from undefined covariants in our populations and/or experimental methods.
The abnormal B-cell and T-cell activation phenotype that is observed in lupus patients is not seen in their family members, suggesting that these abnormalities develop after the immunologic events that lead to overt lupus. However, significant genetically determined reductions in the numbers of NKT cells were observed in the first-degree relatives of lupus patients that correlate with serological and clinical autoimmunity, suggesting that altered immunoregulation by NKT cells may predispose these individuals to autoimmunity. Subtle changes were also observed in the relative proportions of naïve and/or memory B-cell and T-cell populations, and in a recent study these T cells changes were associated with a single nucleotide polymorphism in Ly9, which was linked to lupus . Thus, the analysis of cellular phenotypes in the relatives of lupus patients may reveal extremely useful subclinical phenotypes to increase the power of genetic linkage studies, not only for lupus but also for other autoimmune diseases, as well as providing important clues to the genesis of these conditions.
peripheral blood mononuclear cell
systemic lupus erythematosus
Systemic Lupus Erythematosus Disease Activity Index 2000
This study was performed with funding from an operating grant (#62840) from the Canadian Institutes of Health Research (CIHR). Dr Wither is funded by The Arthritis Centre of Excellence of the University of Toronto and is the recipient of The Arthritis Society/CIHR Investigator Award. Dr Fortin is funded by an Investigator Award from The Arthritis Society/CIHR Institute of Musculoskeletal Health and Arthritis and by The Arthritis Centre of Excellence of the University of Toronto. Dr Hudson is the recipient of a Clinical-Scientist Award in Translational Research from the Burroughs Wellcome Fund.
CaNIOS Investigators are as follows: Murray Urowitz (University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network); Sasha Bernatsky and Ann Clarke (Division of Clinical Epidemiology, Montreal General Hospital, and McGill University, Montreal, Quebec, Canada); Eric Rich (Division of Rheumatology, Hôpital Notre-Dame, Montreal, Quebec, Canada); Carol Hitchon (Winnipeg Health Science Center, Winnipeg, MB, Canada Winnipeg); Simon Carette, Robert Inman, and Lori Albert (Division of Rheumatology, Toronto Western Hospital); and Susan Barr (Calgary Health Sciences Centre, University of Calgary, Calgary, AB, Canada).
We thank the patients and their families as well as the following research associates, who were involved in recruitment of the patients: Diona Dobaille, Menisha Hodge, Tammy Koonthanan, Kiran Pabla, and Yang Zhou (Division of Rheumatology, Toronto Western Hospital); Sara Hewitt and Janine Ouimet (Division of Rheumatology, St Joseph's Health Centre, London, Ontario, Canada); Nancy Branco and Elizabeth Piniero (Division of Clinical Epidemiology, Montreal General Hospital, and McGill University, Montreal, Quebec, Canada); Kathryn Drouin (Division of Rheumatology, Ottawa Hospital, Ottawa, Ontario, Canada); Tina Linehan (Division of Rheumatology, Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada); Diane Therrien (Division of Rheumatology, Hôpital Notre-Dame, Montreal, Quebec, Canada); Andrea Craig, Diane Ferland, and Donna Hart (Winnipeg Health Science Center, Winnipeg, MB, Canada Winnipeg); Celine Boulet and Isabelle Gagnon (Department of Medicine, Division of Rheumatology, University of Sherbrooke, Sherbrooke, Quebec, Canada); Whitney Steber and Patrice Nedinis (Calgary Health Sciences Centre, University of Calgary, Calgary, Alberta, Canada).
- Vyse TJ, Kotzin BL: Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol. 1998, 16: 261-292.View ArticlePubMedGoogle Scholar
- Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001, 15: 397-408.View ArticlePubMedGoogle Scholar
- Sestak AL, Nath SK, Harley JB: Genetics of systemic lupus erythematosus: how far have we come?. Rheum Dis Clin North Am. 2005, 31: 223-244.View ArticlePubMedGoogle Scholar
- Harley JB, arcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008, 40: 204-210.PubMed CentralView ArticlePubMedGoogle Scholar
- Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK, Behrens TW: Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008, 358: 900-909.View ArticlePubMedGoogle Scholar
- Fairhurst AM, Wandstrat AE, Wakeland EK: Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006, 92: 1-69.View ArticlePubMedGoogle Scholar
- Henry T, Mohan C: Systemic lupus erythematosus: recent clues from congenic strains. Arch Immunol Ther Exp (Warsz). 2005, 53: 207-212.Google Scholar
- Wither JE, Lajoie G, Heinrichs S, Cai YC, Chang N, Ciofani A, Cheung YH, MacLeod R: Functional dissection of lupus susceptibility loci on the New Zealand black mouse chromosome 1: evidence for independent genetic loci affecting T and B cell activation. J Immunol. 2003, 171: 1697-1706.View ArticlePubMedGoogle Scholar
- Wither JE, Loh C, Lajoie G, Heinrichs S, Cai YC, Bonventi G, MacLeod R: Colocalization of expansion of the splenic marginal zone population with abnormal B cell activation and autoantibody production in B6 mice with an introgressed New Zealand Black chromosome 13 interval. J Immunol. 2005, 175: 4309-4319.View ArticlePubMedGoogle Scholar
- Laustrup H, Heegaard NH, Voss A, Green A, Lillevang ST, Junker P: Autoantibodies and self-reported health complaints in relatives of systemic lupus erythematosus patients: a community based approach. Lupus. 2004, 13: 792-799.View ArticlePubMedGoogle Scholar
- Miles S, Isenberg D: A review of serological abnormalities in relatives of SLE patients. Lupus. 1993, 2: 145-150.View ArticlePubMedGoogle Scholar
- Namjou B, Nath SK, Kilpatrick J, Kelly JA, Reid J, Reichlin M, James JA, Harley JB: Genome scan stratified by the presence of anti-double-stranded DNA (dsDNA) autoantibody in pedigrees multiplex for systemic lupus erythematosus (SLE) establishes linkages at 19p13.2 (SLED1) and 18q21.1 (SLED2). Genes Immun. 2002, 3 (suppl 1): S35-S41.View ArticlePubMedGoogle Scholar
- Ramos PS, Kelly JA, Gray-McGuire C, Bruner GR, Leiran AN, Meyer CM, Namjou B, Espe KJ, Ortmann WA, Reichlin M, Langefeld CD, James JA, Gaffney PM, Behrens TW, Harley JB, Moser KL: Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun. 2006, 7: 417-432.View ArticlePubMedGoogle Scholar
- Bourne T, Zukowska-Cooper M, Salaman MR, Seifert MH, Isenberg DA: Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38. Clin Exp Immunol. 1998, 111: 611-616.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakane T, Suzuki N, Takada S, Ueda Y, Murakawa Y, Tsuchida T, Yamauchi Y, Kishimoto T: B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1988, 31: 80-87.View ArticlePubMedGoogle Scholar
- Folzenlogen D, Hofer MF, Leung DY, Freed JH, Newell MK: Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol. 1997, 83: 199-204.View ArticlePubMedGoogle Scholar
- Spronk PE, Horst G, Gun Van Der BT, Limburg PC, Kallenberg CG: Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol. 1996, 104: 446-453.PubMed CentralView ArticlePubMedGoogle Scholar
- Viallard JF, Bloch-Michel C, Neau-Cransac M, Taupin JL, Garrigue S, Miossec V, Mercie P, Pellegrin JL, Moreau JF: HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol. 2001, 125: 485-491.PubMed CentralView ArticlePubMedGoogle Scholar
- Bijl M, Horst G, Limburg PC, Kallenberg CG: Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis. 2001, 60: 523-526.PubMed CentralView ArticlePubMedGoogle Scholar
- Su CC, Shau WY, Wang CR, Chuang CY, Chen CY: CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Lupus. 1997, 6: 449-454.View ArticlePubMedGoogle Scholar
- Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman D, Urowitz M, Wither JE: Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J Immunol. 2008, 180: 1276-1284.View ArticlePubMedGoogle Scholar
- Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3580-3590.View ArticlePubMedGoogle Scholar
- Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V: Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. 2001, 167: 2361-2369.View ArticlePubMedGoogle Scholar
- Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T: Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001, 44: 1127-1138.View ArticlePubMedGoogle Scholar
- Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I: Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol. 2001, 28: 275-283.PubMedGoogle Scholar
- Kang HK, Datta SK: Regulatory T cells in lupus. Int Rev Immunol. 2006, 25: 5-25.View ArticlePubMedGoogle Scholar
- Mellor-Pita S, Citores MJ, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu JL, Vargas JA: Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006, 65: 553-554.PubMed CentralView ArticlePubMedGoogle Scholar
- Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Nochy D, Debre P, Piette JC, Gorochov G: Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005, 175: 8392-8400.View ArticlePubMedGoogle Scholar
- van Elteren PH: On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst. 1960, 37: 351-361.Google Scholar
- Hammond KJ, Godfrey DI: NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens. 2002, 59: 353-363.View ArticlePubMedGoogle Scholar
- Linsen L, Somers V, Stinissen P: Immunoregulation of autoimmunity by natural killer T cells. Hum Immunol. 2005, 66: 1193-1202.View ArticlePubMedGoogle Scholar
- Yu KO, Porcelli SA: The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett. 2005, 100: 42-55.View ArticlePubMedGoogle Scholar
- Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N: Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002, 109: 131-140.PubMed CentralView ArticlePubMedGoogle Scholar
- Jacobson DL, Gange SJ, Rose NR, Graham NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997, 84: 223-243.View ArticlePubMedGoogle Scholar
- Clark J, Bourne T, Salaman MR, Seifert MH, Isenberg DA: B lymphocyte hyperactivity in families of patients with systemic lupus erythematosus. J Autoimmun. 1996, 9: 59-65.View ArticlePubMedGoogle Scholar
- Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR: Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol. 2005, 141: 165-173.PubMed CentralView ArticlePubMedGoogle Scholar
- Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR: Natural killer T cells in families of patients with systemic lupus erythematosus: Their possible role in regulation of IGG production. Arthritis Rheum. 2007, 56: 303-310.View ArticlePubMedGoogle Scholar
- Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, Rugeles MT, Atkinson MA, Landay AL, Wilson SB: Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007, 122: 1-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Graham DS, Vyse TJ, Fortin PR, Montpetit A, Cai YC, Lim S, McKenzie T, Farwell L, Rhodes B, Chad L, Hudson TJ, Sharpe A, Terhorst C, Greenwood CM, Wither J, Rioux JD: Association of LY9 in UK and Canadian SLE families. Genes Immun. 2008, 9: 93-102.View ArticleGoogle Scholar
- van d V, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, Eertwegh van den AJ, Giaccone G, Scheper RJ, Pinedo HM: Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001, 100: 144-148.View ArticleGoogle Scholar
- Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Taniguchi M: Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med. 1995, 182: 1163-1168.View ArticlePubMedGoogle Scholar
- Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S: Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 1999, 118: 131-136.PubMed CentralView ArticlePubMedGoogle Scholar
- Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T: Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol. 2003, 15: 279-288.View ArticlePubMedGoogle Scholar
- Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998, 391: 177-181.View ArticlePubMedGoogle Scholar
- Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG: alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med. 1998, 187: 1047-1056.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A: Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med. 2001, 7: 1057-1062.View ArticlePubMedGoogle Scholar
- Shi FD, Flodstrom M, Balasa B, Kim SH, Van GK, Strominger JL, Wilson SB, Sarvetnick N: Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA. 2001, 98: 6777-6782.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang B, Geng YB, Wang CR: CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med. 2001, 194: 313-320.PubMed CentralView ArticlePubMedGoogle Scholar
- Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van KL: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1801-1811.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshimoto T, Bendelac A, Hu-Li J, Paul WE: Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci USA. 1995, 92: 11931-11934.PubMed CentralView ArticlePubMedGoogle Scholar
- Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S: Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004, 50: 305-313.View ArticlePubMedGoogle Scholar
- Mieza MA, Itoh T, Cui JQ, Makino Y, Kawano T, Tsuchida K, Koike T, Shirai T, Yagita H, Matsuzawa A, Koseki H, Taniguchi M: Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol. 1996, 156: 4035-4040.PubMedGoogle Scholar
- Yang JQ, Saxena V, Xu H, Van KL, Wang CR, Singh RR: Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol. 2003, 171: 4439-4446.View ArticlePubMedGoogle Scholar
- Forestier C, Molano A, Im JS, Dutronc Y, Diamond B, Davidson A, Illarionov PA, Besra GS, Porcelli SA: Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black × New Zealand White)F1 mice. J Immunol. 2005, 175: 763-770.View ArticlePubMedGoogle Scholar
- Zeng D, Lee MK, Tung J, Brendolan A, Strober S: Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol. 2000, 164: 5000-5004.View ArticlePubMedGoogle Scholar
- Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest. 2003, 112: 1211-1222.PubMed CentralView ArticlePubMedGoogle Scholar
- Singh AK, Yang JQ, Parekh VV, Wei J, Wang CR, Joyce S, Singh RR, Van KL: The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol. 2005, 35: 1143-1154.PubMed CentralView ArticlePubMedGoogle Scholar
- Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S: The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum. 2005, 52: 1941-1948.View ArticlePubMedGoogle Scholar
- Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 2001, 194: 1789-1799.PubMed CentralView ArticlePubMedGoogle Scholar
- Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001, 413: 531-534.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.